CMS Doubts Power Of Purse To Stem Public Health Crises With Compounded Drugs

Medicare agency disagrees with HHS Office of Inspector General recommendation that providers be required to identify the source of compounded drugs submitted for Part B payment.

Stopping Medicare payment for compounded drugs produced in violation of the FD&C Act would not be a reliable tool for addressing public safety issues associated with such products, the Centers for Medicare and Medicaid Services believe.

CMS said it disagreed with a recommendation by the HHS Office of the Inspector General that the Medicare program consider...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America